News on microarrays, multiplexing, genotyping, cytogenetics, gene expression profiling in genetics, genomics, and molecular diagnostics.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.
The company said it intends to use the proceeds of the offering to advance its MosaiQ high-throughput automated testing products, among other things.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.